Alterations in peripheral cell counts over the duration of treatment with EGFR TKIs, including decreased ANC, ALC, and platelets, may be more readily apparent in patients treated with 3rd gen TKIs compared to those treated with 1st or 2nd gen TKIs, possibly suggesting differences in tumor microenvironment response. Here, EGFR is linked to neoplasm.